10/15 Taiwan Life Sciences Biweekly Newsletter
2024-10-15 |
| Taiwan Life Sciences Biweekly |
| Ministry launches new AI centers to aid e-health 8 October, 2024 The Ministry of Health and Welfare yesterday announced the establishment of three artificial intelligence (AI) centers to help achieve its smart medicine (e-health) goals, adding that 16 "indicator hospitals" have been selected to test and demonstrate the technology. The centers include the center for responsible AI execution, the center for clinical AI certification and the center for AI impact research, Minister of Health and Welfare Chiu Tai-yuan said. More... |
| Anxo Pharmaceutical partners with Sunny Pharmtech to pursue high-margin cardiovascular drug opportunities 7 October, 2024 Drug delivery developer Anxo Pharmaceutical (TW: 6677) announced that it had signed a cooperation agreement with Sunny Pharmtech (TW: 6676) to jointly develop high-margin cardiovascular drugs that challenge the original manufacturer's patent (Paragraph IV), targeting a global market opportunity exceeding US$3.2 billion (approximately NT$103.6 billion). According to the agreement, Anxo Pharmaceutical will be responsible for early-stage research and development, patent strategy, and technology transfer, while Sunny Pharmtech will handle the subsequent technology acquisition and commercial production. Both parties will share the development costs and will split the sales profits once the products are launched in the market. More... (in Chinese) |
| Inventec expands smart healthcare into Malaysia 6 October, 2024 Inventec (TW: 2356) has reported success in its medical sector expansion. Its subsidiary, Good Future BioMed, is addressing the increasing demand for cancer tumor cell detection and gut health testing. In collaboration with Malaysia's leading smart healthcare company WellSpring, they are launching three major products: Circulating Tumor Cell (CTC) detection, Gut Comfort, and Probiotics. Additionally, they have secured several new collaboration projects in Malaysia. Looking ahead, Inventec emphasizes that its medical focus will continue to push forward in the areas of cancer and gut health. More... (in Chinese) |
| Shin Kong Wu Ho-Su Memorial Hospital signs MOUs with two Myanmar Medical Institutions 6 October, 2024 Shin Kong Memorial Hospital has signed two memorandum of understanding (MOU) agreements with medical institutions in Myanmar to initiate collaboration on talent training, referrals, and telemedicine consultations. Local healthcare organizations indicated that this partnership will help improve the quality of medical services in Myanmar and provide essential training opportunities for local healthcare professionals. More... (in Chinese) |
| EirGenix's comprehensive CDMO services strengthening Taiwan's position in the global biopharmaceutical landscape 4 October, 2024 EirGenix, an established Taiwanese Contract Development and Manufacturing Organization (CDMO), specializes in high-quality, cost-effective CDMO services and biologics to ensure affordable biopharmaceuticals capable of meeting global biopharma demands through its dual-product development and CDMO business models. With its two business units, EirGenix is achieving its goal of making biopharmaceutical drugs accessible to all patients. A contract development and manufacturing operation unit assists clients in manufacturing their biologics; a product development unit focuses on developing biologics, including biosimilars, biobetters, and new drugs. More... |
| Taiwan smart medicine achievements recognized at HIMSS 2024 4 October, 2024 Four Taiwan hospitals took multiple awards in the Healthcare Information and Management Systems Society APAC conference and exhibition underway through Oct. 4 in Seoul, underscoring the nationÕs capability in smart health innovations. Among facilities recognized at the event were: northern city, TaoyuanÕs Chang Gung Memorial Hospital; central city, TaichungÕs China Medical University Hospital and Veterans General Hospital; and southern city, TainanÕs Municipal Hospital, the National Science and Technology Council said. More... |
| TFBS Bioscience partners to expand into the North American market 4 October, 2024 TFBS Bioscience (TW: 6939) announced that it has signed a memorandum of understanding (MOU) with CDMO firm Minaris Regenerative Medicine for strategic collaboration in cell and gene therapy (CGT) business in North America. TFBS stated that through this partnership, they aim to provide a one-stop solution to enhance both companies' service offerings and innovation in the CGT field. More... (in Chinese) |
| Global and Taiwan AI healthcare markets estimated to see robust CAGR from 2023 to 2030, says DIGITIMES Research 4 October, 2024 The market size of AI applications for healthcare was US$19.2 billion in 2023, and DIGITIMES Research estimates that the market will grow at a compound annual growth rate (CAGR) of 35.8 percent to reach US$159.7 billion in 2030. Taiwan's AI healthcare market was NT$360 million (US$11.32 million) in 2023 and is expected to grow at a CAGR of 17.3 percent to reach NT$1.12 billion in 2030, according to DIGITIMES Research's latest report covering the AI healthcare market. More... |
| MegaPro Biomedical to present research results at WMIS in Europe 4 October, 2024 MegaPro Biomedical (TW: 6827), a company specializing in the development of nanomedicine, announced that it will present at the World Molecular Imaging Society (WMIS) meeting in Oslo, Norway, from October 6 to 9. He will present the research findings on MPB-2354 in the field of cell therapy through an oral presentation. MPB-2354 is developed using the company's proprietary nanotechnology platform, which combines iron oxide nanoparticles (IOP) with allogeneic adipose-derived stem cells. This cell therapy product boasts both anti-inflammatory properties and in vivo imaging capabilities, offering multiple advantages compared to similar products on the market. More... (in Chinese) |
| Taiwan's Pharmosa Biopharm expands collaboration with Liquida for smart-technology nebulizers 4 October, 2024 Liquidia Corporation, a US-based biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, and Taiwan-based Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialisation of L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The amended agreement expands LiquidiaÕs licensed territory beyond North America to include key markets in Europe, Japan and elsewhere. Pharmosa will retain certain territories, including China, Korea, Taiwan, Middle East, North Africa, Turkey and Southeast Asia. More... |
| Caliway successfully lists on Taipei Exchange following IPO Press release 2 October, 2024 Caliway Biopharmaceuticals (Caliway) announced the successful completion of its initial public offering (IPO) and up-listing from the Emerging Stock Market to the Taipei Exchange (TWSE-6919). The round, which concluded on September 24, 2024, raised approximately $206 million (NT$6.4 billion), marking it as the largest IPO in Taiwan's biotech industry history and valuing the company at nearly $3 billion as of its official listing date today. More... |
| Acepodia's innovative ADC drug platform gains attention, supported by two Nobel Laureates 2 October, 2024 Acepodia (TW: 6976) held its annual symposium recently with its innovative antibody-drug conjugate (ADC) drug platform becoming the focal point and receiving significant industry attention. Nobel Prize-winning chemist Dr. Carolyn Bertozzi was invited as the keynote speaker, with the event being introduced by fellow Nobel Laureate, Dr. Yuan-Tseh Lee from Taiwan. AcepodiaÕs CEO, Dr. Patrick Y. Yang, presented the companyÕs breakthrough research based on bioorthogonal chemistry, leading to the development of its advanced AD2C platform. More... (in Chinese) |
| Academia Sinica launches biomed research facility 1 October, 2024 Academia Sinica yesterday announced the launch of the Biomedical Translation Research Center (BioTReC) Nucleic Acid Pilot Plant during an event unveiling plaques for the National Biotechnology Research Park (NBRP) Academy and the Academic Research Translation Office in Taipei. More... |
| Shine-On BioMedical reports success with nano-scale cancer drug 1 October, 2024 Shine-On BioMedical (TW: 6926) in collaboration with China Medical University Hospital, has developed an innovative nanometer-scale cancer drug, a tri-specific T-cell engaging antibody Nb-TriTE (SOA101), which has successfully completed preclinical research. The next step involves planning the first human clinical trial in this field globally. The drug targets various solid cancers, including lung cancer and breast cancer, marking a significant breakthrough in cancer treatment. More... (in Chinese) |
| StemCyte's RegeneCyte receives FDA advanced designation 30 September, 2024 StemCyte announced that its umbilical cord blood cell drug, RegeneCyte, had officially received Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA, making it the only cell therapy company in Taiwan to obtain this certification. This highlights its breakthrough potential in treating patients with long COVID. The new drug has completed its Phase II clinical trial and will soon undergo unblinding. Drugs that obtain RMAT designation are characterized by fast-track and breakthrough therapy features, significantly expediting the development process. More... (in Chinese) |
| Bio Preventive Medicine's DNlite-IVD103 passes the EU's new IVDR certification 30 September, 2024 Bio Preventive Medicine (TW: 6810) announced that its main product, DNlite-IVD103, has obtained EU IVDR certification, making it the first in Taiwan to receive IVDR certification issued under the EU's new regulations. It is also the first innovative diagnostic product globally to pass IVDR certification in the precise management of kidney function. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2025 (23-27 July, 2025) ========================================= Taiwan Bio Industry Organization (TBIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |